Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • Gold at 15% discount, silver at 28%: DSP Mutual Fund explains why it is buying precious metals now
    • Vision Super exec takes up post at Funds SA
    • Gold-silver price ratio crosses 82: What does this indicate? Where should investors start ETF SIPs for 2027? Experts say
    • Parks and Nature 2026: Community investments
    • Robert Pattinson Once Went to Rikers Island to Research Good Time
    • Pierce Brosnan Bonds With Robert Pattinson Over 007 Role
    • The Little-Known ETF That Aims to Give You $1 of Global Stocks and $1 of Treasuries for Every Dollar Invested
    • Vanguard Investments Canada Announces Estimated 2026 Year-End Distributions For Vanguard Mutual Funds
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»ETFs»Tema ETFs’ Yuri Khodjamirian on weight loss drugs, AI and more
    ETFs

    Tema ETFs’ Yuri Khodjamirian on weight loss drugs, AI and more

    July 15, 2024


    Weight loss drugs and artificial intelligence have been dominating headlines, with investors betting that stocks in both categories have big potential upside. On Wednesday’s Pro Talks , CNBC’s Senior Technology Correspondent Arjun Kharpal will ask Tema ETFs’ Yuri Khodjamirian how to best invest in these areas and more. Got a question for Khodjamirian? Submit it here. Khodjamirian is the chief investment officer of Tema ETFs and manages its Monopolies & Oligopolies ETF , which looks to provide investors with long-term growth through companies that operate in monopolistic industry structures. As well as the obesity drugs of Eli Lilly and Novo Nordisk , he’ll discuss other promising weight loss treatments still in development — and the pharma stocks that stand to benefit. On artificial intelligence, Khodjamirian will name his favorite “second-order winners,” such as financial and data companies, as well as semiconductor equipment manufacturers. Another key theme to watch, according to Khodjamirian, is the U.S. reshoring trend, as geopolitical risks and fragile supply chains lead to a shift in manufacturing that is set to give a number of stocks a boost. Tema ETFs offers actively managed ETFs, with a focus on healthcare and life sciences. Before Tema ETFs, Khodjamirian spent over a decade at Majedie Asset Management, overseeing U.K. and global portfolios. As co-manager of the Majedie U.K. Income Fund, he helped build it from the start to a point of holding several billion dollars in assets. Click here to join CNBC Pro Talks on Wednesday, July 17, at 7 a.m. ET / 12 p.m. BST / 7 p.m. SGT. Submit your questions here. Learn more from our previous Pro Talks: ‘Highest return’: Outperforming fund manager names the best ETFs to play India right now This stock is ‘one of the cheapest ways’ to play India’s infrastructure boom, fund manager says From banks to beauty: Fund manager says AI is giving these companies ‘phenomenal’ uplift Related coverage from Pro: There’s a major bottleneck in AI data center expansion, analysts say. Here’s how to play it Worried about Nvidia? This stock offers a clue about when AI will go mainstream, says Scotiabank Wealth manager reveals where – and how – the super-rich are investing

    CNBC’s Arjun Kharpal and Tema ETFs’ Yuri Khodjamirian.

    Weight loss drugs and artificial intelligence have been dominating headlines, with investors betting that stocks in both categories have big potential upside.

    On Wednesday’s Pro Talks, CNBC’s Senior Technology Correspondent Arjun Kharpal will ask Tema ETFs’ Yuri Khodjamirian how to best invest in these areas and more.

    Got a question for Khodjamirian? Submit it here.

    Khodjamirian is the chief investment officer of Tema ETFs and manages its Monopolies & Oligopolies ETF, which looks to provide investors with long-term growth through companies that operate in monopolistic industry structures.

    As well as the obesity drugs of Eli Lilly and Novo Nordisk, he’ll discuss other promising weight loss treatments still in development — and the pharma stocks that stand to benefit.

    On artificial intelligence, Khodjamirian will name his favorite “second-order winners,” such as financial and data companies, as well as semiconductor equipment manufacturers.

    Another key theme to watch, according to Khodjamirian, is the U.S. reshoring trend, as geopolitical risks and fragile supply chains lead to a shift in manufacturing that is set to give a number of stocks a boost.

    Tema ETFs offers actively managed ETFs, with a focus on healthcare and life sciences.

    Before Tema ETFs, Khodjamirian spent over a decade at Majedie Asset Management, overseeing U.K. and global portfolios. As co-manager of the Majedie U.K. Income Fund, he helped build it from the start to a point of holding several billion dollars in assets.

    Click here to join CNBC Pro Talks on Wednesday, July 17, at 7 a.m. ET / 12 p.m. BST / 7 p.m. SGT.

    Submit your questions here.

    Learn more from our previous Pro Talks:

    Related coverage from Pro:



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    The Little-Known ETF That Aims to Give You $1 of Global Stocks and $1 of Treasuries for Every Dollar Invested

    November 19, 2026

    Bitcoin Falls Back Into 85 Million Won Range as ETF Outflows Prompt Citigroup to Cut Target Price — BigGo Finance

    November 19, 2026

    XRP price’s plan to break past $1 depends on ETF flows, sentiment, and…

    November 18, 2026
    Leave A Reply Cancel Reply

    Top Posts

    Gold at 15% discount, silver at 28%: DSP Mutual Fund explains why it is buying precious metals now

    November 19, 2026

    Gold-silver price ratio crosses 82: What does this indicate? Where should investors start ETF SIPs for 2027? Experts say

    November 19, 2026

    Bitcoin Falls Back Into 85 Million Won Range as ETF Outflows Prompt Citigroup to Cut Target Price — BigGo Finance

    November 19, 2026

    Vision Super exec takes up post at Funds SA

    November 19, 2026
    Don't Miss
    Mutual Funds

    Gold at 15% discount, silver at 28%: DSP Mutual Fund explains why it is buying precious metals now

    November 19, 2026

    According to its November 18, 2026, report, gold is trading near $3,799.80 per ounce against…

    Vision Super exec takes up post at Funds SA

    November 19, 2026

    Gold-silver price ratio crosses 82: What does this indicate? Where should investors start ETF SIPs for 2027? Experts say

    November 19, 2026

    Parks and Nature 2026: Community investments

    November 19, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    Counterpoint Funds, LLC Announces Counterpoint High Yield Trend ETF and Counterpoint Quantitative Equity ETF Transferring to NYSE

    October 25, 2024

    New owner plans to keep Sips vibrant and engaging for customers – The Troy Messenger

    August 3, 2024

    Volatile prices, high inflows take toll on gold, silver ETFs return

    February 28, 2026
    Our Picks

    Gold at 15% discount, silver at 28%: DSP Mutual Fund explains why it is buying precious metals now

    November 19, 2026

    Vision Super exec takes up post at Funds SA

    November 19, 2026

    Gold-silver price ratio crosses 82: What does this indicate? Where should investors start ETF SIPs for 2027? Experts say

    November 19, 2026
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    🇮🇸 CPP Investments and Equinix complete atNorth acquisition to support growth of leading Nordic data center platform

    September 1, 2026
    © 2026 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.